5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
US8362068B2 · kind B2 · utility
44Cited by
25References
53Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 17, 2010 |
| Grant date | Jan 29, 2013 |
| Priority date | — |
| Expiry date | Dec 17, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/06165
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.